Clinical Definition of COPD Exacerbations and Classification of Their Severity

被引:19
作者
Caramori, Gaetano [1 ]
Adcock, Ian M.
Papi, Alberto
机构
[1] Univ Ferrara, Ctr Ric Asma & BPCO, I-44100 Ferrara, Italy
关键词
clinical trials; COPD; definition; exacerbation; severity; OBSTRUCTIVE PULMONARY-DISEASE; THORACIC-SOCIETY RECOMMENDATIONS; AIRWAY INFLAMMATION; FLUTICASONE PROPIONATE; FREQUENCY; TIOTROPIUM; PREVENTION; MANAGEMENT; OUTCOMES; INFECTIONS;
D O I
10.1097/SMJ.0b013e3181836b73
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A standardized definition of chronic obstructive pulmonary disease (COPD) exacerbation still represents an unmet need in respiratory medicine; definitions currently rely oil clinical empiricism with little evidence-based scientific support. Exacerbations of COPD are certainly clear events in the mind of practicing physicians. However, when one tries to provide simple concepts such as their definition and classification of severity, one realizes how little we know. Current symptom- and event-based definitions of a COPD exacerbation, as well as the classifications of the severity of COPD exacerbations, all have their own limitations. Efforts to assess the efficacy of new therapies in the treatment and prevention of COPD exacerbations have been hampered by the lack of a widely agreed upon and consistently used definition. There is a need for greater investment in research oil COPD exacerbations in order to promote a better understanding of COPD exacerbations.
引用
收藏
页码:277 / 282
页数:6
相关论文
共 57 条
[1]  
Allegra L., 1991, ITALJCHEST DIS, V45, P138
[2]   Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD [J].
Ambrosetti, M ;
Ageno, W ;
Spanevello, A ;
Salerno, M ;
Pedretti, RFE .
THROMBOSIS RESEARCH, 2003, 112 (04) :203-207
[3]  
[Anonymous], 2006, COCHRANE DATABASE SY
[4]   ANTIBIOTIC-THERAPY IN EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY-DISEASE [J].
ANTHONISEN, NR ;
MANFREDA, J ;
WARREN, CPW ;
HERSHFIELD, ES ;
HARDING, GKM ;
NELSON, NA .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (02) :196-204
[5]   Pulmonary biomarkers in chronic obstructive pulmonary disease [J].
Barnes, Peter J. ;
Chowdhury, Badrul ;
Kharitonov, Sergei A. ;
Magnussen, Helgo ;
Page, Clive P. ;
Postma, Dirkje ;
Saetta, Marina .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 174 (01) :6-14
[6]   Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial [J].
Burge, PS ;
Calverley, PMA ;
Jones, PW ;
Spencer, S ;
Anderson, JA ;
Maslen, TK .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7245) :1297-1303
[7]  
BURGE S, 2003, EUR RESPIR J, V41, P46, DOI DOI 10.1183/09031936.03.00078002
[8]   Relationship between respiratory symptoms and medical treatment in exacerbations of COPID [J].
Calverley, P ;
Pauwels, R ;
Lofdahl, CG ;
Svensson, K ;
Higenbottam, T ;
Carlsson, LG ;
Ståhl, E .
EUROPEAN RESPIRATORY JOURNAL, 2005, 26 (03) :406-413
[9]   Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial [J].
Calverley, P ;
Pauwels, R ;
Vestbo, J ;
Jones, P ;
Pride, N ;
Gulsvik, A ;
Anderson, J ;
Maden, C .
LANCET, 2003, 361 (9356) :449-456
[10]   Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [J].
Calverley, Peter M. A. ;
Anderson, Julie A. ;
Celli, Bartolome ;
Ferguson, Gary T. ;
Jenkins, Christine ;
Jones, Paul W. ;
Yates, Julie C. ;
Vestbo, Jorgen ;
Calverley, P. M. A. ;
Anderson, J. A. ;
Celli, B. ;
Ferguson, G. T. ;
Jenkins, C. ;
Jones, P. W. ;
Knobil, K. ;
Yates, J. C. ;
Vestbo, J. ;
Cherniack, R. ;
Similowski, T. ;
Cleland, J. ;
Whitehead, A. ;
Wise, R. ;
McGarvey, L. ;
John, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) :775-789